Display options
Cite
Maroun J, Kocha W, Kvols L, et al. Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol. 2006;13(2):67-76
Maroun, J., Kocha, W., Kvols, L., Bjarnason, G., Chen, E., Germond, C., Hanna, S., Poitras, P., Rayson, D., Reid, R., Rivera, J., Roy, A., Shah, A., Sideris, L., Siu, L., & Wong, R. (2006). Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Current oncology (Toronto, Ont.), 13(2), 67-76.
Maroun, J, et al. "Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group." Current oncology (Toronto, Ont.) vol. 13,2 (2006): 67-76.
Maroun J, Kocha W, Kvols L, Bjarnason G, Chen E, Germond C, Hanna S, Poitras P, Rayson D, Reid R, Rivera J, Roy A, Shah A, Sideris L, Siu L, Wong R. Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol. 2006 Apr;13(2):67-76. PMID: 17576444; PMCID: PMC1891174.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol. 2006 Apr;13(2):67-76.

Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.

Current oncology (Toronto, Ont.)

J Maroun, W Kocha, L Kvols, G Bjarnason, E Chen, C Germond, S Hanna, P Poitras, D Rayson, R Reid, J Rivera, A Roy, A Shah, L Sideris, L Siu, R Wong

Affiliations

  1. Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario. [email protected]

PMID: 17576444 PMCID: PMC1891174

Abstract

Carcinoid tumours are relatively rare and, in general, slow growing. They can be "non-functioning" tumours, presenting as a tumour mass, or "functioning" tumours secondary to the production of several biopeptides leading to the carcinoid syndrome. Though these tumours represent 0.25% of an oncology practice, a proper understanding of the clinical course of the disease and of the importance of appropriate diagnostic and therapeutic measures is very important. Proper patient management can lead to cure, particularly if the tumour can be fully resected, or to long-term palliation with medical treatment or cytoreductive surgery, or both, with significant prolongation of survival. A good understanding of the use of somatostatin analogues to achieve effective symptomatic control and of the importance of adequate follow-up and cardiac monitoring to prevent or effectively treat cardiac complications can contribute significantly to optimal control of this complex disease, ultimately improving the quality of life of affected patients. This article, developed by a group of Canadian experts, provides a framework that will assist clinicians in taking an optimal approach to managing their patients with carcinoid tumour.

References

  1. Neuroendocrinology. 2004;80(6):394-424 - PubMed
  2. World J Surg. 1996 Feb;20(2):157-61 - PubMed
  3. Eur J Cancer Prev. 2003 Jun;12(3):191-4 - PubMed
  4. Br J Dermatol. 2005 Jan;152(1):71-5 - PubMed
  5. Endocr Rev. 2004 Jun;25(3):458-511 - PubMed
  6. Surg Oncol Clin N Am. 2003 Jan;12(1):231-42 - PubMed
  7. J Am Coll Cardiol. 1998 Oct;32(4):1017-22 - PubMed
  8. J Clin Endocrinol Metab. 2001 Feb;86(2):895-902 - PubMed
  9. Cancer Control. 2002 Jan-Feb;9(1):67-79 - PubMed
  10. J Gastrointest Surg. 2004 Sep-Oct;8(6):742-56 - PubMed
  11. Neuroendocrinology. 2004;80 Suppl 1:28-32 - PubMed
  12. Acta Oncol. 2003;42(7):672-92 - PubMed
  13. Best Pract Res Clin Endocrinol Metab. 2005 Jun;19(2):265-76 - PubMed
  14. Circulation. 1993 Apr;87(4):1188-96 - PubMed
  15. Clin Endocrinol (Oxf). 2004 May;60(5):644-52 - PubMed
  16. Cardiovasc Surg. 2002 Jun;10(3):287-90 - PubMed
  17. Acta Oncol. 2004;43(7):626-36 - PubMed
  18. Gut. 2005 Jun;54 Suppl 4:iv1-16 - PubMed
  19. Curr Treat Options Cardiovasc Med. 2000 Oct;2(5):399-406 - PubMed
  20. Cancer. 2001 Sep 1;92(5):1101-7 - PubMed
  21. Yale J Biol Med. 1997 Sep-Dec;70(5-6):509-22 - PubMed
  22. J Am Coll Surg. 2003 Jul;197(1):29-37 - PubMed
  23. Clin Chem. 1999 Apr;45(4):549-60 - PubMed
  24. J Am Coll Surg. 1997 May;184(5):487-92 - PubMed
  25. Circulation. 1995 Aug 15;92(4):790-5 - PubMed
  26. Ann Clin Biochem. 2003 Nov;40(Pt 6):612-27 - PubMed
  27. Cancer. 2003 Feb 15;97(4):934-59 - PubMed
  28. Br J Cancer. 2004 Jun 1;90(11):2073-9 - PubMed
  29. Digestion. 2000;62 Suppl 1:92-7 - PubMed
  30. Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S160-2 - PubMed
  31. Cancer. 1991 Jul 15;68(2):227-32 - PubMed
  32. Circulation. 1988 Feb;77(2):264-9 - PubMed
  33. Hepatogastroenterology. 2001 May-Jun;48(39):720-3 - PubMed
  34. Ann Oncol. 2004 Jun;15(6):966-73 - PubMed
  35. Digestion. 2000;62 Suppl 1:33-8 - PubMed
  36. World J Surg. 2004 Nov;28(11):1163-8 - PubMed
  37. Br J Cancer. 1999 Dec;81(8):1351-5 - PubMed
  38. Acta Oncol. 2004;43(7):617-25 - PubMed
  39. Bratisl Lek Listy. 2001;102(11):495-504 - PubMed
  40. N Engl J Med. 2003 Mar 13;348(11):1005-15 - PubMed
  41. Eur Radiol. 2003 Jan;13(1):136-40 - PubMed
  42. Am J Med. 1986 Dec 22;81(6B):41-8 - PubMed
  43. Surgery. 1998 Dec;124(6):1000-4 - PubMed
  44. Neuroendocrinology. 2004;80 Suppl 1:35-8 - PubMed
  45. Expert Rev Anticancer Ther. 2003 Dec;3(6):863-77 - PubMed
  46. Scand J Gastroenterol Suppl. 2002;(236):66-71 - PubMed
  47. Heart. 2004 Oct;90(10):1224-8 - PubMed
  48. Eur J Endocrinol. 2004 Jul;151(1):15-27 - PubMed
  49. Eur J Nucl Med. 2001 Apr;28(4):478-82 - PubMed
  50. J Gastrointest Surg. 2004 Feb;8(2):208-12 - PubMed
  51. Am J Surg. 2004 Jan;187(1):39-46 - PubMed
  52. Am J Gastroenterol. 2004 Jan;99(1):23-32 - PubMed
  53. Adv Surg. 1995;28:317-36 - PubMed
  54. Cancer. 1997 Feb 15;79(4):830-4 - PubMed
  55. World J Surg. 1996 Feb;20(2):183-8 - PubMed

Publication Types